Prelude Therapeutics reported revenue of $5.70M and net income of -$14.11M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 3.00M | 4.00M | 6.50M | 5.64M | 4.58M | 5.70M | ||||||||||||||||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 22.72M | 25.18M | 22.82M | 21.31M | 22.89M | 25.87M | 21.83M | 24.97M | 26.26M | 30.33M | 27.41M | 29.51M | 29.46M | 31.62M | 28.82M | 25.78M | 21.71M | 17.99M | 13.60M | 16.13M | ||||||||
| Selling, General & AdministrativeSG&A | 8.12M | 7.83M | 7.47M | 8.15M | 7.52M | 7.52M | 7.28M | 7.43M | 7.12M | 7.05M | 6.93M | 7.66M | 7.92M | 6.21M | 5.79M | 6.41M | 5.21M | 5.00M | 5.16M | 5.03M | ||||||||
| Operating ExpensesOpex | 30.84M | 33.01M | 30.29M | 29.46M | 30.41M | 33.38M | 29.11M | 32.40M | 33.38M | 37.38M | 34.34M | 37.16M | 37.38M | 37.83M | 34.61M | 32.19M | 26.92M | 22.99M | 18.76M | 21.16M | ||||||||
| Operating IncomeOp. Inc | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M | ||||||||
| EBIT | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.15M | 0.17M | 0.82M | 2.09M | 0.45M | 4.74M | 1.40M | 1.97M | 2.78M | 4.30M | 2.91M | 2.42M | 2.10M | 5.10M | 2.52M | 0.96M | 0.69M | 0.89M | 3.79M | 1.53M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M | ||||||||
| Profit After TaxPAT | -30.86M | -33.38M | -29.46M | -27.37M | -30.03M | -27.97M | -27.72M | -30.43M | -30.61M | -33.08M | -31.43M | -34.74M | -32.27M | -28.86M | -32.09M | -31.24M | -19.73M | -16.45M | -10.38M | -14.11M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M | ||||||||
| Income towards Parent CompanyParent Net Inc | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M | ||||||||
| Net Income towards Common StockholdersNet Income | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.67 | -0.72 | -0.64 | -0.62 | -0.64 | -0.70 | -0.61 | -0.58 | -0.49 | -0.62 | -0.45 | -0.49 | -0.45 | -0.45 | -0.46 | -0.42 | -0.27 | -0.23 | -0.17 | -0.16 | ||||||||
| EPS (Diluted) | -0.67 | -0.72 | -0.64 | -0.62 | -0.64 | -0.70 | -0.61 | -0.58 | -0.49 | -0.62 | -0.45 | -0.49 | -0.45 | -0.45 | -0.46 | -0.42 | -0.27 | -0.23 | -0.17 | -0.16 | ||||||||
| Shares Outstanding | 46.33M | 46.05M | 47.07M | 47.28M | 47.45M | 47.37M | 47.74M | 56.24M | 67.64M | 60.36M | 75.74M | 75.76M | 75.86M | 75.81M | 75.99M | 75.99M | 76.13M | 76.96M | 82.52M | 98.39M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 46.33M | 46.05M | 47.07M | 47.28M | 47.45M | 47.37M | 47.74M | 56.24M | 67.64M | 60.36M | 75.74M | 75.76M | 75.86M | 75.81M | 75.99M | 75.99M | 76.13M | 76.96M | 82.52M | 98.39M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 47.22M | 47.63M | 47.70M | 47.83M | 47.86M | 47.91M | 47.96M | 54.81M | 54.83M | 54.92M | 75.74M | 75.76M | 75.86M | 75.81M | 75.99M | 75.99M | 62.87M | 63.00M | 79.65M | 79.80M | ||||||||
| EBITDA | -30.84M | -33.01M | -30.29M | -29.46M | -30.41M | -33.38M | -29.11M | -32.40M | -33.38M | -37.38M | -34.34M | -37.16M | -34.38M | -33.83M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M | -15.45M |